The FDA has accepted a biologics license application for brolucizumab for the treatment of neovascular age-related macular degeneration, Novartis announced in a press release.
The application was based on phase 3 data from the HAWK and HARRIER trials, which found brolucizumab to be noninferior to aflibercept in mean change in best corrected visual acuity from baseline to week 48.
In addition, significantly fewer patients treated with brolucizumab had disease activity and retinal fluid compared with patients treated with aflibercept.
“Reaching this milestone is an important step in our
Uncategorized